Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418695972> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2418695972 abstract "Aims and Background Beta-interferon (β-IFN) has been proven to influence some IL-2-induced immune effects. On the basis of these experimental data, we evaluated the immunobiologic effects of an association between very low-dose IL-2 and β-IFN in advanced cancer patients. Methods The study was performed in 15 metastatic colon cancer patients, who progressed in response to a first-line chemotherapy with 5-FU plus folates. IL-2 was given subcutaneously at a daily dose of 3 million IU in the evening for 6 days/week for 4 weeks. β-IFN was injected subcutaneously at a dose of 3 million U/day for 7 days before the first IL-2 injection, then thrice/week until the end of IL-2 administration. In nonprogressed patients, a second cycle was given after a 14-day rest period. Results No objective tumor regression was seen. Stable disease was obtained only in 2/15 patients; the other 13 progressed. Toxicity was low in all cases. Natural killer cell and T-activated lymphocyte mean number significantly increased during the immunotherapy. Lymphocyte and eosinophil mean number also increased, without, however, significant differences. IL-2-induced suppressive events, consisting of an increase in T-suppressor cell number, and soluble IL-2 receptor levels were not blocked by β-IFN. Conclusions The study showed that the concomitant administration of β-IFN may determine an improvement in the immune performance in metastatic cancer patients treated with very low-dose IL-2, even though this biologic improvement does not seem to be associated to a control of tumor development. Further studies in patients with less advanced disease are needed to better define the impact of the immune improvement induced by low-dose IL-2 plus β-IFN on the clinical course of the neoplastic disease." @default.
- W2418695972 created "2016-06-24" @default.
- W2418695972 creator A5026158008 @default.
- W2418695972 creator A5028874575 @default.
- W2418695972 creator A5030301955 @default.
- W2418695972 creator A5061179981 @default.
- W2418695972 creator A5066244741 @default.
- W2418695972 creator A5072559950 @default.
- W2418695972 creator A5074666213 @default.
- W2418695972 date "1993-10-01" @default.
- W2418695972 modified "2023-10-18" @default.
- W2418695972 title "Immunotherapy with Low-Dose Subcutaneous Interleukin-2 plus Beta-Interferon as a Second-Line Therapy for Metastatic Colorectal Carcinoma" @default.
- W2418695972 cites W1990373435 @default.
- W2418695972 cites W2002724941 @default.
- W2418695972 cites W2036275492 @default.
- W2418695972 cites W2052048121 @default.
- W2418695972 cites W2066233701 @default.
- W2418695972 cites W2081468737 @default.
- W2418695972 cites W2257187839 @default.
- W2418695972 cites W2270697554 @default.
- W2418695972 cites W2322553446 @default.
- W2418695972 doi "https://doi.org/10.1177/030089169307900512" @default.
- W2418695972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8116079" @default.
- W2418695972 hasPublicationYear "1993" @default.
- W2418695972 type Work @default.
- W2418695972 sameAs 2418695972 @default.
- W2418695972 citedByCount "7" @default.
- W2418695972 crossrefType "journal-article" @default.
- W2418695972 hasAuthorship W2418695972A5026158008 @default.
- W2418695972 hasAuthorship W2418695972A5028874575 @default.
- W2418695972 hasAuthorship W2418695972A5030301955 @default.
- W2418695972 hasAuthorship W2418695972A5061179981 @default.
- W2418695972 hasAuthorship W2418695972A5066244741 @default.
- W2418695972 hasAuthorship W2418695972A5072559950 @default.
- W2418695972 hasAuthorship W2418695972A5074666213 @default.
- W2418695972 hasConcept C121608353 @default.
- W2418695972 hasConcept C126322002 @default.
- W2418695972 hasConcept C143998085 @default.
- W2418695972 hasConcept C203014093 @default.
- W2418695972 hasConcept C2776694085 @default.
- W2418695972 hasConcept C2777371288 @default.
- W2418695972 hasConcept C2777701055 @default.
- W2418695972 hasConcept C2777761686 @default.
- W2418695972 hasConcept C2778690821 @default.
- W2418695972 hasConcept C2779384505 @default.
- W2418695972 hasConcept C526805850 @default.
- W2418695972 hasConcept C71924100 @default.
- W2418695972 hasConcept C8891405 @default.
- W2418695972 hasConcept C90924648 @default.
- W2418695972 hasConceptScore W2418695972C121608353 @default.
- W2418695972 hasConceptScore W2418695972C126322002 @default.
- W2418695972 hasConceptScore W2418695972C143998085 @default.
- W2418695972 hasConceptScore W2418695972C203014093 @default.
- W2418695972 hasConceptScore W2418695972C2776694085 @default.
- W2418695972 hasConceptScore W2418695972C2777371288 @default.
- W2418695972 hasConceptScore W2418695972C2777701055 @default.
- W2418695972 hasConceptScore W2418695972C2777761686 @default.
- W2418695972 hasConceptScore W2418695972C2778690821 @default.
- W2418695972 hasConceptScore W2418695972C2779384505 @default.
- W2418695972 hasConceptScore W2418695972C526805850 @default.
- W2418695972 hasConceptScore W2418695972C71924100 @default.
- W2418695972 hasConceptScore W2418695972C8891405 @default.
- W2418695972 hasConceptScore W2418695972C90924648 @default.
- W2418695972 hasLocation W24186959721 @default.
- W2418695972 hasLocation W24186959722 @default.
- W2418695972 hasOpenAccess W2418695972 @default.
- W2418695972 hasPrimaryLocation W24186959721 @default.
- W2418695972 hasRelatedWork W1996150995 @default.
- W2418695972 hasRelatedWork W2047209980 @default.
- W2418695972 hasRelatedWork W2057167101 @default.
- W2418695972 hasRelatedWork W2112237700 @default.
- W2418695972 hasRelatedWork W2430654588 @default.
- W2418695972 hasRelatedWork W3032907499 @default.
- W2418695972 hasRelatedWork W3180780036 @default.
- W2418695972 hasRelatedWork W4291367166 @default.
- W2418695972 hasRelatedWork W2185732136 @default.
- W2418695972 hasRelatedWork W2396811992 @default.
- W2418695972 isParatext "false" @default.
- W2418695972 isRetracted "false" @default.
- W2418695972 magId "2418695972" @default.
- W2418695972 workType "article" @default.